MPM BioImpact
@mpmbioimpact.bsky.social
We are a world-leading biotechnology investment firm with three decades of experience creating and investing in innovative companies seeking to deliver transformative therapies to patients.
Find more info at https://mpmbioimpact.com/
Find more info at https://mpmbioimpact.com/
ICYMI: Orna Therapeutics announced the appointment of Joseph Bolen, Ph.D., as CEO! Dr. Bolen, an MPM BioImpact Entrepreneur Partner, most recently served as Orna’s Chief Scientific Officer and is the ideal leader to advance its potentially best-in-class panCAR programs into the clinic next year.
Orna Therapeutics Appoints Joseph Bolen, Ph.D., as Chief Executive Officer - Orna Therapeutics
WATERTOWN, Mass., March 31, 2025 – Orna Therapeutics, a biotechnology company dedicated to engineering immune cells in vivo to treat oncology and autoimmune diseases, today announced the appointment o...
www.ornatx.com
March 31, 2025 at 1:56 PM
ICYMI: Orna Therapeutics announced the appointment of Joseph Bolen, Ph.D., as CEO! Dr. Bolen, an MPM BioImpact Entrepreneur Partner, most recently served as Orna’s Chief Scientific Officer and is the ideal leader to advance its potentially best-in-class panCAR programs into the clinic next year.
Earlier this morning, DBV Technologies announced a PIPE, of up to $306.9M led by MPM BioImpact! DBV is committed to a critical mission, developing novel treatments that can potentially transform the care of food-allergic patients.
DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to Advance Viaskin® Peanut Patch Through Biologics License Application Submission and U.S. Commercial Launch, if Approved ...
March 27, 2025 22:30 ETChâtillon, France, March 27, 2025 DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to Advance V ...
dbv-technologies.com
March 28, 2025 at 2:06 PM
Earlier this morning, DBV Technologies announced a PIPE, of up to $306.9M led by MPM BioImpact! DBV is committed to a critical mission, developing novel treatments that can potentially transform the care of food-allergic patients.
Congrats to Cullinan Therapeutics, which announced that its Phase 2b trial in patients with NSCLC met its primary endpoint! Cullinan was founded by MPM BioImpact and is committed to treating a variety of cancer and autoimmune disorders with high unmet medical needs. Learn more: bit.ly/3Cu39V0
January 30, 2025 at 5:30 PM
Congrats to Cullinan Therapeutics, which announced that its Phase 2b trial in patients with NSCLC met its primary endpoint! Cullinan was founded by MPM BioImpact and is committed to treating a variety of cancer and autoimmune disorders with high unmet medical needs. Learn more: bit.ly/3Cu39V0
Congrats to the recipients of the AACR-MPM Oncology Charitable Foundation Transformative Cancer Research Grant: Drs. Nika N. Danial and Karin Pelka! We are proud to support paradigm-shifting research, which may advance our understanding of cancer and transform future clinical practice.
January 29, 2025 at 12:38 PM
Congrats to the recipients of the AACR-MPM Oncology Charitable Foundation Transformative Cancer Research Grant: Drs. Nika N. Danial and Karin Pelka! We are proud to support paradigm-shifting research, which may advance our understanding of cancer and transform future clinical practice.
We are happy to join BlueSky! Keep a look out for exciting news on our portfolio companies and our firm, as well as our insights about the biotech industry!
January 24, 2025 at 10:35 PM
We are happy to join BlueSky! Keep a look out for exciting news on our portfolio companies and our firm, as well as our insights about the biotech industry!